Powercheck AI Files for Nasdaq IPO With $16.9M Offering
Powercheck AI Holdings Limited, a British Virgin Islands holding company operating in Malaysia, filed for an initial public offering on May 27, 2026. The company plans to sell 3.75 million ordinary shares at $4.00 to $5.00 per share and list on Nasdaq under the ticker "PCAI."
The offering would raise approximately $16.9 million at the midpoint price. Powercheck AI will allocate 30% of proceeds to AI and data system development, 25% to Southeast Asia expansion, and 20% to physical health center construction.
The Business Model
Powercheck AI operates an AI-driven health screening platform that combines whole genome sequencing, rapid health screening, and personalized health products. The company targets both direct-to-consumer and institutional customers through a tiered product line.
Its main offerings include PowerDNA Premium (whole genome sequencing with 3,320+ reports), PowerCheck (a mobile, three-minute palm-based screening tool), and DNATide (a personalized supplement line). The company plans to open physical health centers in Malaysia offering screenings, IV therapy, and ongoing health management.
Powercheck AI positions itself as Malaysia's first in-depth AI-powered whole genome testing provider with an integrated closed-loop health platform. The company targets a customer lifetime value to customer acquisition cost ratio above 3x.
Financial Position and Growth Trajectory
Revenue reached $1,865 in fiscal 2025, up from $179 in fiscal 2024. The company reported a gross profit of negative $790 and operating losses of $22,734 in the most recent period.
The global direct-to-consumer genetic testing market reached approximately $4.5 billion in 2024 and is projected to grow to $12.3 billion by 2033, according to company estimates. The Asia Pacific genetic testing market is expected to expand from $2.80 billion in 2024 to $5.43 billion by 2033.
Management and Operations
Tey Giap Chian serves as chairman and chief executive officer. Tey Giap Turn, who spent over 20 years in supply chain and operations roles including work at Schlumberger REDA, is chief operating officer and chief financial officer. Tey Shi Bin, an associate professor and vice president at New Era University, serves as director.
Powercheck AI operates from Johor Bahru, Malaysia, with plans to expand physical health centers to Kuala Lumpur, Penang, and other regional markets. The company has a strategic hardware partnership with Yun Kang for rapid screening devices and an academic collaboration with New Era University on an AI Health Data Laboratory.
Market Competition and Strategy
Powercheck AI competes against established players including 23andMe, Ancestry.com, Invitae, and Color Genomics. The company differentiates through proprietary AI analysis, comprehensive reference databases, and what it describes as a data advantage built through longitudinal health interactions.
The company plans to expand to Singapore, Thailand, Vietnam, Indonesia, and the Philippines. It will allocate 15% of IPO proceeds to product research and development focused on functional supplements and personalized health products.
For management professionals evaluating AI-driven business strategies, understanding AI for Executives & Strategy provides context for how companies like Powercheck AI position AI capabilities as competitive advantages. The company's focus on AI for Healthcare reflects broader industry adoption of AI in genomics and personalized medicine.
Your membership also unlocks:
